Streptokinase - Market Size, Share, Growth, Analysis, Key Players, Revenue, | Valuates Reports

Streptokinase - Market Size
The global market for Streptokinase was estimated to be worth US$ 364 million in 2023 and is forecast to a readjusted size of US$ 526.1 million by 2030 with a CAGR of 5.9% during the forecast period 2024-2030

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-36V6917/Global_Streptokinase_Market_Insights_Forecast_to_2028

Market Trends in the Streptokinase Industry:

1. Rising Prevalence of Cardiovascular Diseases (CVDs)
o Increasing cases of heart attacks, strokes, and deep vein thrombosis (DVT) are fueling demand for thrombolytic agents like streptokinase.
2. Growing Adoption of Streptokinase in Emergency Medicine
o Streptokinase is widely used in emergency settings for dissolving blood clots, making it a crucial component of acute medical interventions.
3. Advancements in Biotechnology and Drug Development
o Ongoing research and biotechnology innovations are enhancing the efficacy and safety of streptokinase formulations.
4. Increasing Demand in Emerging Markets
o Developing regions with a growing burden of cardiovascular diseases are adopting cost-effective thrombolytic therapies, boosting market growth.
5. Expansion of Hospital and Critical Care Infrastructure
o The rise in specialty cardiac hospitals and critical care centers is contributing to increased streptokinase usage globally.
________________________________________

Market Challenges in the Streptokinase Industry:

1. Availability of Alternative Thrombolytic Agents
o Competing clot-dissolving drugs, such as tissue plasminogen activators (tPAs), may limit market growth for streptokinase.
2. Side Effects and Allergic Reactions
o Some patients experience allergic responses and complications, leading to cautious use and regulatory scrutiny.
3. Regulatory Approvals and Compliance
o Stringent regulatory processes for drug approvals and manufacturing standards may delay market entry for new players.
4. High Cost of Advanced Thrombolytic Treatments
o While streptokinase is cost-effective, newer clot-busting drugs with fewer side effects may be preferred despite their higher price.
5. Limited Awareness in Certain Regions
o In some developing markets, lack of awareness and accessibility to thrombolytic therapy hinders market growth.

Segment by Type:

•
High IU
• Low IU

Segment by Application

• Myocardial Infarction (MI)
• Deep Vein Thrombosis
• Pulmonary Embolism
• Others

By Company

SAMARTH PHARMA, Biocon, Kee Pharma, Dabur, Biosena, Wanbang Biopharma, Qingdao GD Biotechnology Pharmaceutical, Aristo Pharmaceuticals, Neiss Labs, Ahaan Healthcare Pvt Ltd. (AHPL), Biofactor, TTK HealthCare, Incepta Pharmaceuticals Limited, Cadila

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-36V6917/global

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.